Psoriatic Arthritis Therapeutics Market - Snapshot

The global psoriatic arthritis therapeutics market is expanding at a rapid pace due to high prevalence and increase in incidence rate of psoriatic arthritis and new product development and commercialization across the globe. In terms of revenue, the global market was valued at US$ 6,011.7 Mn in 2017 and is projected to reach US$ 17,118.7 Mn by 2026, expanding at a CAGR of 11.4% from 2018 to 2026. The global psoriatic arthritis therapeutics market is also driven by rise in adoption of biologics for the treatment of moderate to severe psoriatic arthritis and large patient population with unmet medical needs across the globe. 

psoriatic arthritis therapeutics market

Psoriatic arthritis is a chronic autoimmune inflammatory disorder that causes inflammation, swelling, and stiffness at any joint of the body. Psoriatic arthritis is a progressive form of psoriasis, characterized by the itchy, scaly red patches on the skin. It is estimated that more than 125 million people around the world are affected with psoriasis, and 30% of the psoriasis population tend to develop psoriatic arthritis. The common symptoms of psoriatic arthritis include swollen fingers, toes, and tender joints, stiffness, lower back pain, and pitted nails. Psoriatic arthritis is a non-curable disease and treatments are aimed at relieving the symptoms of the condition. Various over-the-counter and prescription drugs are available and several more are in different stages of clinical trials in order to treat the symptoms of psoriatic arthritis. 

The global psoriatic arthritis therapeutics market is driven by intensive research to provide treatments and/or relieve the symptoms of the condition. There is a large patient population suffering from moderate to severe psoriatic arthritis with unmet medical needs, and the number is increasing across the globe. Leading pharmaceutical companies are striving to address these unmet medical needs through new product development. Large number of both small molecules and biologic products are under different phases of clinical trials for the treatment of psoriatic arthritis. Companies have made significant investments in clinical R&D and have also established strategic partnerships and collaborations to accelerate new product development. Interleukin inhibitors drugs have proven to be effective and well-tolerated treatment for psoriatic arthritis and recently, around three different interleukin inhibitors have been approved and commercialized in the U.S. and Europe. Numerous different drugs candidates are under interleukin inhibitors that are in phase III clinical trials for psoriatic arthritis treatment, which are likely to commercialize in first half of the forecast period. High prevalence and rise in incidence rates of psoriatic arthritis with significant unmet medical needs are projected to propel the global psoriatic arthritis therapeutics market during the forecast period. 

The global psoriatic arthritis therapeutics market has been segmented based on drug class, route of administration, distribution channel, and region. In terms of drug class, the global market has been classified into TNF inhibitors, interleukin inhibitors, PDE4 inhibitors, and others. The TNF inhibitors segment dominated the global market in 2017. Large patient population with psoriasis, long-term management of moderate to severe psoriatic arthritis, and high cost of TNF inhibitors contributed to the high market share held by the segment in 2017. The interleukin inhibitors segment is estimated gain market share significantly by the end of 2026. The PDE4 inhibitors segment is estimated to expand at a rapid pace during the forecast period, owing to high clinical efficacy, increased demand, and low cost of drugs. 

In terms of route of administration, the global psoriatic arthritis therapeutics market has been segmented into oral, parenteral, and topical. The parenteral segment accounted for a prominent share of the global market in 2017. It is estimated to expand at a notable growth rate during the forecast period. The large share held by the parenteral segment is attributed to the high cost of biologic drugs, which are administered through intravenous and subcutaneous routes, large number of biologic and biosimilar drugs under clinical pipeline trials, and estimated increase in adoption of biosimilar drugs during the forecast period. 

Based on distribution channel, the global psoriatic arthritis therapeutics market has been divided into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated the global market in 2017. It is projected to gain market share by the end of 2026. Long-term management of severe psoriatic arthritis, increase in rate of hospitalization, and availability of high cost biologic drugs are attributed to the large share of the market held by the segment in 2017. The hospital pharmacies segment is anticipated to expand at a significant growth rate during the forecast period. 

In terms of region, the global psoriatic arthritis therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to account for more than of 50% share of the global market by 2026. High prevalence of psoriatic arthritis, increase in adoption of biologic drugs for the treatment of moderate to severe psoriatic arthritis, and anticipated new product approvals are likely to fuel the psoriatic arthritis therapeutics market in North America. The market in Asia Pacific is projected to expand at a prominent CAGR during the forecast period. Increase in awareness about psoriatic arthritis, rapidly changing health care infrastructure, rise in access to psoriatic arthritis treatments in developing countries such as China and India, well-established pharmaceutical market in Japan, and surge in adoption of biologic drugs in Australia and New Zealand are anticipated to fuel the psoriatic arthritis therapeutics market in Asia Pacific during the forecast period. 

Majority of biopharmaceutical companies have made significant investments in the clinical research and development of Psoriatic Arthritis treatment products. Mergers and acquisitions among leading players has been a key trend in the global market in the last few years. Key players operating in the global psoriatic arthritis therapeutics market include AbbVie, Inc., Janssen Biotech, Inc., Novartis AG, Amgen, Inc., Celgene Corporation, Pfizer, Inc., Eli Lilly and Company, UCB, Inc., Biogen Inc., and Bristol-Myers and Squibb Company.

Unmet Need for Novel Medications to Enrich the Landscape in Psoriatic Arthritis Therapeutics Market

The psoriatic arthritis (PSA) therapeutics market has benefitted from the growing availability of medications ranging from traditional ones to biological disease-modifying antirheumatic drugs. PSA has a high health burden on the patients since the affected suffer from several comorbidities. These comorbidities increase the risk of cardiac failure and usually cause the rise of prevalence of cardiovascular diseases in the world’s population. Some of these are type 2 diabetes/insulin resistance, obesity, metabolic syndrome, hyperlipidemia, and hypertension. The marked heterogeneity of PsA phenotype of the disease has spurred research and development activities in the psoriatic arthritis (PSA) therapeutics market. In recent years, released targeted synthetic DMARDs have attracted the attention of medical researchers. Growing understanding of immunopathogenesis of several autoimmune diseases is  a key trend on which new avenues are expected to emerge in the foreseeable future. Industry players are keen on overcoming the limitations of first-line biologic therapy, since as much as 40% of the affected patients experience no improvement in the clinical symptoms. Thus, the unmet need is a key stimulant for new product development in the psoriatic arthritis (PSA) therapeutics market. Ongoing phase III clinical trial will help boost the revenue potential in the coming few years.  

The Covid-19 pandemic and its aftermath on the healthcare systems and economic systems has been debilitating for some countries. Since, it was declared a pandemic, some economies have been successful in containing the spread of the virus by undergoing extensive lockdowns and implementing nation-wide prevention and control strategies in the early this year. However, the global economy is still in substantial turmoil and affects the trade and economic activities across international borders. Further, the uncertainties in demand and consumption have kept manufacturers wary of the return of investments. Having said that, the new normals that arise in the post-pandemic world has also given rise to the incredible potential of automation technologies to meet the demands for prospective customers. The pandemic has been an eye- opener for governments and common citizens alike to focus squarely on improving the healthcare infrastructure. The aspect will spur vast growth potential in the market.

Psoriatic Arthritis Therapeutics Market - Overview

This report by Transparency Market Research analyses the global psoriatic arthritis therapeutics market for the period between 2018 and 2026. An in-depth and unbiased market assessment has been made, which offers readers an in-depth and accurate analysis. Market projections have been offered in terms of value (US$ Mn). Stakeholders of this report include companies and intermediaries engaged in research & development, manufacture, and marketing of products prescribed in the treatment of psoriatic arthritis. 

The global psoriatic arthritis therapeutics market has been studied for the forecast period from 2018 to 2026. For research, 2017 has been considered as the base year and 2016 as the historical year. The global psoriatic arthritis therapeutics market report comprises an elaborate executive summary that provides overall information about various segments of the market. The report provides a detailed competitive landscape, by major players operating in this market along with their shares (value %) of the global psoriatic arthritis therapeutics market for 2017. The report also provides detailed company profiles of emerging market players operating in the global psoriatic arthritis therapeutics market. 

The market overview section comprises impact factors such as key market dynamics, including drivers, restraints, and opportunities, affecting the global psoriatic arthritis therapeutics market. These factors are likely to aid stakeholders establish a strong foothold in the global psoriatic arthritis therapeutics market. Furthermore, the market overview section comprises key industry events, pipeline analysis, key mergers & acquisitions across the industry, epidemiology analysis of the psoriatic arthritis, product portfolio overview of leading players, and market attractiveness analysis in the global psoriatic arthritis therapeutics market. The market attractiveness analysis provides a graphical view comparing the expansion and market dynamics in various segments and countries to identify the most attractive market. 

Scope

The global psoriatic arthritis therapeutics market has been segmented based on drug class, route of administration, distribution channel, and region. In terms of drug class, the global market has been classified into TNF inhibitors, interleukin inhibitors, PDE4 inhibitors, and others. Based on route of administration, the global market has been segregated into oral, parenteral, and topical. In terms of distribution channel, the global psoriatic arthritis therapeutics market has been categorized into hospital pharmacies, retail pharmacies, and online pharmacies. 

In terms of region, the global psoriatic arthritis therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Moreover, quantitative analysis for major countries comprising the U.S., Canada, Germany, France, the U.K., Italy, Spain, Russia, China, Japan, India, and Australia & New Zealand has also been provided in the report. A detailed qualitative analysis of factors responsible for driving and restraining the global market in various regions has been provided in this section. 

The report provides a detailed outline/blueprint of the global psoriatic arthritis therapeutics market, which is expected to assist new companies establish their presence and companies to expand their share in the market. The report concludes with the company profiles section, which includes company overview, financial overview, SWOT analysis, product portfolio, business strategies, and recent developments of key players. 

Competitive landscape

Major players operating in the global psoriatic arthritis therapeutics market include AbbVie, Inc., Janssen Biotech, Inc., Novartis AG, Amgen, Inc., Celgene Corporation, Pfizer, Inc.,  Eli Lilly and Company, UCB, Inc., Biogen Inc., and Bristol-Myers and Squibb Company.

The global psoriatic arthritis therapeutics market has been segmented into: 

Drug Class

  • TNF Inhibitors
  • Interleukin Inhibitors
  • PDE4 Inhibitors
  • Others

Administration

  • Oral
  • Parenteral
  • Topical

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

 Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • U.K.
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

1. Preface
      1.1. Market Definition and Scope
      1.2. Market Segmentation
      1.3. Key Research Objectives
      1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Psoriatic Arthritis Therapeutics Market

4. Market Overview
      4.1. Introduction
             4.1.1. Drug Class 
             4.1.2. Industry Evolution / Developments      
      4.2. Overview
      4.3. Market Dynamics
             4.3.1. Drivers
             4.3.2. Restraints
             4.3.3. Opportunities
      4.4. Global Psoriatic Arthritis Therapeutics Market Analysis and Forecast, 2016–2026

5. Market Outlook
      5.1. Pipeline Analysis
      5.2. Key Mergers & Acquisitions 
      5.3. Disease Prevalence & Incidence Rate globally with key Countries

6. Global Psoriatic Arthritis Therapeutics Market Analysis and Forecast, by Drug Class    
      6.1. Introduction & Definition
      6.2. Key Findings / Developments
      6.3. Global Psoriatic Arthritis Therapeutics Market Value Forecast, by Drug Class, 2016–2026
             6.3.1. TNF Inhibitors
             6.3.2. Interleukin Inhibitors
             6.3.3. PDE4 Inhibitors
             6.3.4. Others
      6.4. Global Psoriatic Arthritis Therapeutics Market Attractiveness, by Drug Class   

7. Global Psoriatic Arthritis Therapeutics Market Analysis and Forecast, by Route of Administration  
      7.1. Introduction & Definition
      7.2. Key Findings / Developments
      7.3. Global Psoriatic Arthritis Therapeutics Market Value Forecast, by Route of Administration , 2016–2026
             7.3.1. Oral
             7.3.2. Parenteral
             7.3.3. Topical
      7.4. Global Psoriatic Arthritis Therapeutics Market Attractiveness, by Route of Administration  

8. Global Psoriatic Arthritis Therapeutics Market Analysis and Forecast, by Distribution Channel 
      8.1. Introduction & Definition
      8.2. Key Findings / Developments
      8.3. Global Psoriatic Arthritis Therapeutics Market Value Forecast, by Distribution Channel, 2016–2026
             8.3.1. Hospital Pharmacies
             8.3.2. Retail Pharmacies
             8.3.3. Online Pharmacies
      8.4. Global Psoriatic Arthritis Therapeutics Market Attractiveness, by Distribution Channel 

9. Global Psoriatic Arthritis Therapeutics Market Analysis and Forecast, by Region
      9.1. Key Findings
      9.2. Global Psoriatic Arthritis Therapeutics Market Value Forecast, by Region
             9.2.1. North America 
             9.2.2. Europe 
             9.2.3. Asia Pacific 
             9.2.4. Latin America 
             9.2.5. Middle East & Africa 
      9.3. Global Psoriatic Arthritis Therapeutics Market Attractiveness, by Region

10. North America Psoriatic Arthritis Therapeutics Market Analysis and Forecast
      10.1. Introduction
      10.2. North America Psoriatic Arthritis Therapeutics Market Value Forecast, by Drug Class, 2016–2026
             10.2.1. TNF Inhibitors
             10.2.2. Interleukin Inhibitors
             10.2.3. PDE4 Inhibitors
             10.2.4. Others
      10.3. North America Psoriatic Arthritis Therapeutics Market Value Forecast, by Route of Administration, 2016–2026
             10.3.1. Oral
             10.3.2. Parenteral
             10.3.3. Topical
      10.4. North America Psoriatic Arthritis Therapeutics Market Value Forecast, by Distribution Channel, 2016–2026
             10.4.1. Hospital Pharmacies
             10.4.2. Retail Pharmacies
             10.4.3. Online Pharmacies
      10.5. North America Psoriatic Arthritis Therapeutics Market Value Forecast, by Country, 2016–2026
             10.5.1. U.S.
             10.5.2. Canada
      10.6. North America Psoriatic Arthritis Therapeutics Market Attractiveness Analysis 
             10.6.1. By Drug Class    
             10.6.2. By Route of Administration  
             10.6.3. By Distribution Channel 
             10.6.4. By Country

11. Europe Psoriatic Arthritis Therapeutics Market Analysis and Forecast
      11.1. Introduction
      11.2. Europe Psoriatic Arthritis Therapeutics Market Value Forecast, by Drug Class, 2016–2026
             11.2.1. TNF Inhibitors
             11.2.2. Interleukin Inhibitors
             11.2.3. PDE4 Inhibitors
             11.2.4. Others
      11.3. Europe Psoriatic Arthritis Therapeutics Market Value Forecast, by Route of Administration, 2016–2026
             11.3.1. Oral
             11.3.2. Parenteral
             11.3.3. Topical
      11.4. Europe Psoriatic Arthritis Therapeutics Market Value Forecast, by Distribution Channel, 2016–2026
             11.4.1. Hospital Pharmacies
             11.4.2. Retail Pharmacies
             11.4.3. Online Pharmacies
      11.5. Europe Psoriatic Arthritis Therapeutics Market Value Forecast, by Country/Sub-region, 2016–2026
             11.5.1. Germany
             11.5.2. U.K.
             11.5.3. France
             11.5.4. Spain
             11.5.5. Italy
             11.5.6. Rest of Europe
      11.6. Europe Psoriatic Arthritis Therapeutics Market Attractiveness Analysis 
             11.6.1. By Drug Class    
             11.6.2. By Route of Administration               
             11.6.3. By Distribution Channel 
             11.6.4. By Country/Sub-region

12. Asia Pacific Psoriatic Arthritis Therapeutics Market Analysis and Forecast
      12.1. Introduction
      12.2. Asia Pacific Psoriatic Arthritis Therapeutics Market Value Forecast, by Drug Class, 2016–2026
             12.2.1. TNF Inhibitors
             12.2.2. Interleukin Inhibitors
             12.2.3. PDE4 Inhibitors
             12.2.4. Others
      12.3. Asia Pacific Psoriatic Arthritis Therapeutics Market Value Forecast, by Route of Administration, 2016–2026
             12.3.1. Oral
             12.3.2. Parenteral
             12.3.3. Topical
      12.4. Asia Pacific Psoriatic Arthritis Therapeutics Market Value Forecast, by Distribution Channel, 2016–2026
             12.4.1. Hospital Pharmacies
             12.4.2. Retail Pharmacies
             12.4.3. Online Pharmacies
      12.5. Asia Pacific Psoriatic Arthritis Therapeutics Market Value Forecast, by Country/Sub-region, 2016–2026
             12.5.1. China
             12.5.2. Japan
             12.5.3. India
             12.5.4. Australia & New Zealand
             12.5.5. Rest of Asia Pacific
      12.6. Asia Pacific Psoriatic Arthritis Therapeutics Market Attractiveness Analysis 
             12.6.1. By Drug Class    
             12.6.2. By Route of Administration  
             12.6.3. By Distribution Channel 
             12.6.4. By Country/Sub-region

13. Latin America Psoriatic Arthritis Therapeutics Market Analysis and Forecast
      13.1. Introduction
             13.1.1. Key Findings
      13.2. Latin America Psoriatic Arthritis Therapeutics Market Value Forecast by Drug Class, 2016–2026
             13.2.1. TNF Inhibitors
             13.2.2. Interleukin Inhibitors
             13.2.3. PDE4 Inhibitors
             13.2.4. Others
      13.3. Latin America Psoriatic Arthritis Therapeutics Market Value Forecast, by Route of Administration, 2016–2026
             13.3.1. Oral
             13.3.2. Parenteral
             13.3.3. Topical
      13.4. Latin America Psoriatic Arthritis Therapeutics Market Value Forecast, by Distribution Channel, 2016–2026
             13.4.1. Hospital Pharmacies
             13.4.2. Retail Pharmacies
             13.4.3. Online Pharmacies
      13.5. Latin America Psoriatic Arthritis Therapeutics Market Value Forecast, by Country/Sub-region, 2016–2026
             13.5.1. Brazil
             13.5.2. Mexico
             13.5.3. Rest of Latin America
      13.6. Latin America Psoriatic Arthritis Therapeutics Market Attractiveness Analysis 
             13.6.1. By Drug Class    
             13.6.2. By Route of Administration  
             13.6.3. By Distribution Channel 
             13.6.4. By Country/Sub-region

14. Middle East & Africa Psoriatic Arthritis Therapeutics Market Analysis and Forecast
      14.1. Introduction
             14.1.1. Key Findings
      14.2. Middle East & Africa Psoriatic Arthritis Therapeutics Market Value Forecast, by Drug Class, 2016–2026
             14.2.1. TNF Inhibitors
             14.2.2. Interleukin Inhibitors
             14.2.3. PDE4 Inhibitors
             14.2.4. Others
      14.3. Middle East & Africa Psoriatic Arthritis Therapeutics Market Value Forecast, by Route of Administration, 2016–2026
             14.3.1. Oral
             14.3.2. Parenteral
             14.3.3. Topical
      14.4. Middle East & Africa Psoriatic Arthritis Therapeutics Market Value Forecast, by Distribution Channel, 2016–2026
             14.4.1. Hospital Pharmacies
             14.4.2. Retail Pharmacies
             14.4.3. Online Pharmacies
      14.5. Middle East & Africa Psoriatic Arthritis Therapeutics Market Value Forecast, by Country/Sub-region, 2016–2026
             14.5.1. GCC Countries
             14.5.2. South Africa
             14.5.3. Rest of Middle East & Africa
      14.6. Middle East & Africa Psoriatic Arthritis Therapeutics Market Attractiveness Analysis 
             14.6.1. By Drug Class    
             14.6.2. By Route of Administration  
             14.6.3. By Distribution Channel 
             14.6.4. By Country/Sub-region

15. Competition Landscape
      15.1. Market Player – Competition Matrix (by Tier and Size of companies)
      15.2. Global Psoriatic Arthritis Therapeutics Market Share Analysis by Company (2017)
      15.3. Company Profiles
             15.3.1. AbbVie, Inc.
             15.3.2. Janssen Biotech, Inc. (Johnson & Johnson)
             15.3.3. Novartis AG
             15.3.4. Amgen, Inc.
             15.3.5. CELGENE CORPORATION
             15.3.6. Pfizer, Inc.
             15.3.7. Eli Lilly and Company
             15.3.8. UCB Inc.
             15.3.9. Biogen Inc.
             15.3.10. Bristol-Myers Squibb Company

List of Tables

Table 01: Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 02: Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 03: Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 04: Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Region, 2016–2026
Table 05: North America Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016–2026
Table 06: North America Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 07: North America Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 08: North America Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 09: Europe Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 10: Europe Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 11: Europe Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 12: Europe Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 13: Asia Pacific Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 14: Asia Pacific Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 15: Asia Pacific Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 16: Asia Pacific Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 17: Latin America Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 18: Latin America Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 19: Latin America Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 20: Latin America Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 21: Middle East & Africa Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 22: Middle East & Africa Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 23: Middle East & Africa Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 24: Middle East & Africa Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026

List of Figures

Figure 01: Global Psoriatic Arthritis Therapeutics Market Snapshot
Figure 02: Global Psoriatic Arthritis Market Value (US$ Mn) and Distribution, by Region, 2017 and 2025
Figure 03: Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, 2016-2026
Figure 05: Global Psoriatic Arthritis Therapeutics Market Value Share (%), by Route of Administration (2017)
Figure 06: Global Psoriatic Arthritis Therapeutics Market Value Share (%), by Distribution Channel (2017)
Figure 04: Global Psoriatic Arthritis Therapeutics Market Value Share (%), by Drug Class (2017)
Figure 07: Global Psoriatic Arthritis Therapeutics Market Value Share (%), by Region (2017)
Figure 08: Global Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2026
Figure 09: Global Psoriatic Arthritis Therapeutics Market Attractiveness, by Drug Class, 2018–2026
Figure 10: Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by TNF Inhibitors, 2016–2026
Figure 11: Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Interleukin Inhibitors, 2016–2026
Figure 12: Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by PDE4 Inhibitors, 2016–2026
Figure 13: Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2016–2026
Figure 14: Global Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Route of Administration, 2017 and 2026
Figure 15: Global Psoriatic Arthritis Therapeutics Market Attractiveness, by Route of Administration, 2018–2026
Figure 16: Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Oral, 2016–2026
Figure 17: Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Parenteral, 2016–2026
Figure 18: Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Topical, 2016–2026
Figure 19: Global Psoriatic Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2017 and 2026
Figure 20: Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2016–2026
Figure 21: Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Retail Pharmacies, 2016–2026
Figure 22: Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Online Pharmacies, 2016–2026
Figure 23: Global Psoriatic Arthritis Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
Figure 24: Global Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Region 2017 and 2026
Figure 25: Global Psoriatic Arthritis Therapeutics Market Attractiveness, by Region, 2018–2026
Figure 26: North America Psoriatic Arthritis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 27: North America Psoriatic Arthritis Therapeutics Market Value Share (%), by Country, 2017 and 2026
Figure 28: North America Psoriatic Arthritis Therapeutics Market Attractiveness, by Country, 2018–2026
Figure 29: North America Psoriatic Arthritis Therapeutics Market Value Share (%), by Drug Class, 2017 and 2026
Figure 30: North America Psoriatic Arthritis Therapeutics Market Attractiveness, by Drug Class, 2018–2026
Figure 31: North America Psoriatic Arthritis Therapeutics Market Value Share (%), by Route of Administration, 2017 and 2026
Figure 32: North America Psoriatic Arthritis Therapeutics Market Attractiveness, by Route of Administration, 2018–2026
Figure 33: North America Psoriatic Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2017 and 2026
Figure 34: North America Psoriatic Arthritis Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
Figure 35: Europe Psoriatic Arthritis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 36: Europe Psoriatic Arthritis Therapeutics Market Value Share (%), by Country/Sub-region, 2017 and 2026
Figure 37: Europe Psoriatic Arthritis Therapeutics Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 38: Europe Psoriatic Arthritis Therapeutics Market Value Share (%), by Drug Class, 2017 and 2026
Figure 39: Europe Psoriatic Arthritis Therapeutics Market Attractiveness, by Drug Class, 2018–2026
Figure 40: Europe Psoriatic Arthritis Therapeutics Market Value Share (%), by Route of Administration, 2017 and 2026
Figure 41: Europe Psoriatic Arthritis Therapeutics Market Attractiveness, by Route of Administration, 2018–2026
Figure 42: Europe Psoriatic Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2017 and 2026
Figure 43: Europe Psoriatic Arthritis Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
Figure 44: Asia Pacific Psoriatic Arthritis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 45: Asia Pacific Psoriatic Arthritis Therapeutics Market Value Share (%), by Country/Sub-region, 2017 and 2026
Figure 46: Asia Pacific Psoriatic Arthritis Therapeutics Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 47: Asia Pacific Psoriatic Arthritis Therapeutics Market Value Share (%), by Drug Class, 2017 and 2026
Figure 48: Asia Pacific Psoriatic Arthritis Therapeutics Market Attractiveness, by Drug Class, 2018–2026
Figure 49: Asia Pacific Psoriatic Arthritis Therapeutics Market Value Share (%), by Route of Administration, 2017 and 2026
Figure 50: Asia Pacific Psoriatic Arthritis Therapeutics Market Attractiveness, by Route of Administration, 2018–2026
Figure 51: Asia Pacific Psoriatic Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2017 and 2026
Figure 52: Asia Pacific Psoriatic Arthritis Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
Figure 53: Latin America Psoriatic Arthritis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 54: Latin America Psoriatic Arthritis Therapeutics Market Value Share (%), by Country/Sub-region, 2017 and 2026
Figure 55: Latin America Psoriatic Arthritis Therapeutics Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 56: Latin America Psoriatic Arthritis Therapeutics Market Value Share (%), by Drug Class, 2017 and 2026
Figure 57: Latin America Psoriatic Arthritis Therapeutics Market Attractiveness, by Drug Class, 2018–2026
Figure 58: Latin America Psoriatic Arthritis Therapeutics Market Value Share (%), by Route of Administration, 2017 and 2026
Figure 59: Latin America Psoriatic Arthritis Therapeutics Market Attractiveness, by Route of Administration, 2018–2026
Figure 60: Latin America Psoriatic Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2017 and 2026
Figure 61: Latin America Psoriatic Arthritis Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
Figure 62: Middle East & Africa Psoriatic Arthritis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 63: Middle East & Africa Psoriatic Arthritis Therapeutics Market Value Share (%), by Country/Sub-region, 2017 and 2026
Figure 64: Middle East & Africa Psoriatic Arthritis Therapeutics Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 65: Middle East & Africa Psoriatic Arthritis Therapeutics Market Value Share (%), by Drug Class, 2017 and 2026
Figure 66: Middle East & Africa Psoriatic Arthritis Therapeutics Market Attractiveness, by Drug Class, 2018–2026
Figure 67: Middle East & Africa Psoriatic Arthritis Therapeutics Market Value Share (%), by Route of Administration, 2017 and 2026
Figure 68: Middle East & Africa Psoriatic Arthritis Therapeutics Market Attractiveness, by Route of Administration, 2018–2026
Figure 69: Middle East & Africa Psoriatic Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2017 and 2026
Figure 70: Middle East & Africa Psoriatic Arthritis Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
Figure 71: Global Psoriatic Arthritis Therapeutics Market Share Analysis, by Company (2017)
Figure 72: AbbVie, Inc’s Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2017
Figure 73: AbbVie, Inc’s R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
Figure 74: AbbVie, Inc’s Breakdown of Net Sales (%), by Region
Figure 75: Johnson & Johnson Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2017
Figure 76: Breakdown of Net Sales (%), by Business Segment, (2017)
Figure 77: Johnson and Johnson R&D Intensity and Sales & Marketing Intensity – Company Level, 2016–2017
Figure 78: Johnson & Johnson Breakdown of Net Sales (%), by Geography (2017)
Figure 79: Novartis AG’s Breakdown of Net Sales, by Geography (2017)
Figure 80: Novartis AG’s Breakdown of Net Sales, by Business Segment (2017)
Figure 81: Novartis AG’s R&D Intensity and Sales & Marketing Intensity – Company Level, 2016–2017
Figure 82: Novartis AG’s Revenue (US$ Bn) & Y-o-Y Growth (%), 2015–2017
Figure 83: Amgen Inc’s R&D Intensity and Sales & Marketing Intensity - Company Level, 2016–2017
Figure 85: Amgen Inc’s Breakdown of Net Sales, by Region, 2017
Figure 86: Celgene Corporation’s Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
Figure 87: Celgene Corporation’s Breakdown of Net Sales (%), by Key Product (2017)
Figure 88: Celgene Corporation’s R&D Intensity and Sales & Marketing Intensity – Company Level, 2016–2017
Figure 89: Celgene Corporation’s Breakdown of Net Sales, by Geography (2017)
Figure 90: Pfizer Inc’s Breakdown of Net Sales, by Region, 2017
Figure 92: Pfizer Inc’s R&D Intensity and Sales & Marketing Intensity - Company Level, 2016–2017
Figure 93: Eli Lilly’s Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
Figure 94: Eli Lilly’s Breakdown of Net Sales (%), by Region, 2017
Figure 95: Eli Lilly’s Research & Development Cost (US$ Mn), 2016 and 2017
Figure 96: Eli Lilly’s Breakdown of Net Sales (%), by Business Segment, 2017
Figure 97: UCB, Inc’s Breakdown of Net Sales, by Region
Figure 98: UCB, Inc’s Breakdown of Net Sales, by Therapeutic Area
Figure 99: UCB, Inc’s R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
Figure 100: UCB, Inc’s Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 101: Biogen Inc’s Breakdown of Net Revenue, by Region
Figure 102: Biogen Inc’s Breakdown of Net Sales, by Revenue Center
Figure 103: Biogen Inc’s R&D Intensity and Sales & Marketing Intensity – Company Level, 2016–2017
Figure 104: Biogen Inc’s Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2017
Figure 105: Bristol-Myers Squibb Company’s Revenue (US$ Bn), 2014-2017
Figure 106: Bristol-Myers Squibb Company R&D Expenditure (US$ Bn), 2015- 2017
Figure 107: Bristol-Myers Squibb Company Revenue, by Geography, 2017

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Psoriatic Arthritis Therapeutics Market